Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 9/3/24 → 9/3/26 |
Funding
- Merck Sharp & Dohme Corporation: $2.00
24-HN-40-MSD (007-00): A Phase 2/3, Adaptive, Randomized, Open-Label, Clinical Study to Evaluate Neoadjuvant and Adjuvant V940 (mRNA-4157) in Combination with Pembrolizumab (MK- 3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants
- Arnold, Susanne (PI)